| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ERBB1; Receptor protein-tyrosine kinase ErbB-1; kinase EGFR |
| Entrez GeneID | 1956; |
| WB Predicted band size | 175kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Peptide sequence around phosphorylation site of tyrosine 1172 (P-D-Y(p)-Q-Q) derived from Human EGFR. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇涉及EGFR (Phospho-Tyr1172)抗体的参考文献及摘要概括：
---
1. **"Phosphorylation of Tyr-1172 in EGFR is required for Akt activation"**
*作者：Sordella R. et al. (2003)*
**摘要**：本研究通过EGFR Tyr1172位点磷酸化特异性抗体，验证了该位点在EGFR下游Akt信号通路中的关键作用。实验表明，Tyr1172磷酸化缺陷会抑制Akt激活，影响细胞存活和增殖。
---
2. **"Site-specific phosphorylation of EGFR reveals biphasic signaling dynamics"**
*作者：Zhang X. et al. (2006)*
**摘要**：利用EGFR多个磷酸化位点(包括Tyr1172)的特异性抗体，作者揭示了EGFR信号的双相动力学特征。Tyr1172磷酸化在配体刺激后迅速达到峰值，并与ERK通路活化密切相关，提示其作为信号放大节点的功能。
---
3. **"Targeted inhibition of EGFR Y1172 phosphorylation enhances antitumor efficacy in lung cancer models"**
*作者：Chen L. et al. (2018)*
**摘要**：通过抗Tyr1172磷酸化抗体检测发现，EGFR该位点在肺癌组织中高表达。实验表明，靶向抑制Tyr1172磷酸化可显著降低肿瘤细胞侵袭性并增强化疗敏感性，为靶向治疗提供了新策略。
---
注：上述文献信息为模拟示例，实际文献需通过PubMed或学术数据库检索确认。若需具体文献，建议使用关键词“EGFR Y1172 phosphorylation antibody”或“EGFR pY1172”进一步查询。
The EGFR (Phospho-Tyr1172) antibody is a specialized tool used to detect phosphorylation at tyrosine residue 1172 (Y1172) of the epidermal growth factor receptor (EGFR), a transmembrane receptor tyrosine kinase. EGFR activation occurs upon ligand binding (e.g., EGF, TGF-α), triggering receptor dimerization, autophosphorylation of specific tyrosine residues in its intracellular domain, and downstream signaling pathways (e.g., MAPK, PI3K/AKT) that regulate cell proliferation, survival, and differentiation. Phosphorylation at Y1172 is a critical post-translational modification linked to receptor activation and signal transduction.
This antibody is widely utilized in cancer research, as aberrant EGFR signaling—including hyperphosphorylation due to mutations or overexpression—is implicated in malignancies like non-small cell lung cancer (NSCLC) and colorectal cancer. It helps assess EGFR activation status in cell lines, tissues, or tumor samples via techniques such as Western blotting, immunohistochemistry (IHC), or immunofluorescence (IF). Researchers also employ it to study mechanisms of resistance to EGFR-targeted therapies (e.g., gefitinib, erlotinib) or evaluate therapeutic efficacy in preclinical models.
Validation of the antibody’s specificity is essential, often confirmed using phosphorylation-deficient mutants or EGFR knockout controls. Its application contributes to understanding EGFR signaling dynamics, biomarker discovery, and development of targeted therapies.
×
